trending Market Intelligence /marketintelligence/en/news-insights/trending/b2azmtibdnjmlvp4mqplwq2 content esgSubNav
In This List

Dimerix names 1st chief medical officer

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Dimerix names 1st chief medical officer

Dimerix Ltd. named David Packham to the newly created position of chief medical officer.

Packham was a principal investigator on Dimerix's phase 2a trial of DMX-200 in chronic kidney disease that successfully concluded in 2017, the company said.

Packham is also director of the Melbourne Renal Research Group, a specialist research facility for nephrology studies. He will lead Melbourne-based Dimerix's development efforts for DMX-200.